108 related articles for article (PubMed ID: 26263187)
21. Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.
Hu Z; Jiang X; Albright CF; Graciani N; Yue E; Zhang M; Zhang SY; Bruckner R; Diamond M; Dowling R; Rafalski M; Yeleswaram S; Trainor GL; Seitz SP; Han W
Bioorg Med Chem Lett; 2010 Feb; 20(3):853-6. PubMed ID: 20060717
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast Activation Protein α Activated Tripeptide Bufadienolide Antitumor Prodrug with Reduced Cardiotoxicity.
Deng LJ; Wang LH; Peng CK; Li YB; Huang MH; Chen MF; Lei XP; Qi M; Cen Y; Ye WC; Zhang DM; Chen WM
J Med Chem; 2017 Jul; 60(13):5320-5333. PubMed ID: 28595013
[TBL] [Abstract][Full Text] [Related]
23. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).
Meyer-Losic F; Quinonero J; Dubois V; Alluis B; Dechambre M; Michel M; Cailler F; Fernandez AM; Trouet A; Kearsey J
J Med Chem; 2006 Nov; 49(23):6908-16. PubMed ID: 17154520
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation.
Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C
Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269
[TBL] [Abstract][Full Text] [Related]
25. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
[TBL] [Abstract][Full Text] [Related]
26. A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier.
Grinda M; Clarhaut J; Tranoy-Opalinski I; Renoux B; Monvoisin A; Cronier L; Papot S
ChemMedChem; 2011 Dec; 6(12):2137-41. PubMed ID: 21815268
[No Abstract] [Full Text] [Related]
27. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
[TBL] [Abstract][Full Text] [Related]
28. A macromolecular prodrug of doxorubicin conjugated to a biodegradable cyclotriphosphazene bearing a tetrapeptide.
Kim JK; Toti US; Song R; Sohn YS
Bioorg Med Chem Lett; 2005 Aug; 15(15):3576-9. PubMed ID: 15982876
[TBL] [Abstract][Full Text] [Related]
29. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
Ravel D; Dubois V; Quinonero J; Meyer-Losic F; Delord J; Rochaix P; Nicolazzi C; Ribes F; Mazerolles C; Assouly E; Vialatte K; Hor I; Kearsey J; Trouet A
Clin Cancer Res; 2008 Feb; 14(4):1258-65. PubMed ID: 18281561
[TBL] [Abstract][Full Text] [Related]
30. Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation.
Miller MA; Mikula H; Luthria G; Li R; Kronister S; Prytyskach M; Kohler RH; Mitchison T; Weissleder R
ACS Nano; 2018 Dec; 12(12):12814-12826. PubMed ID: 30550257
[TBL] [Abstract][Full Text] [Related]
31. Fullerenol-cytotoxic conjugates for cancer chemotherapy.
Chaudhuri P; Paraskar A; Soni S; Mashelkar RA; Sengupta S
ACS Nano; 2009 Sep; 3(9):2505-14. PubMed ID: 19681636
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Berjeaud JM; Guilhot F; Papot S
J Med Chem; 2012 May; 55(9):4516-20. PubMed ID: 22515366
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug.
Huang S; Fang R; Xu J; Qiu S; Zhang H; Du J; Cai S
J Drug Target; 2011 Aug; 19(7):487-96. PubMed ID: 21284542
[TBL] [Abstract][Full Text] [Related]
34. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy.
Kratz F; Müller-Driver R; Hofmann I; Drevs J; Unger C
J Med Chem; 2000 Apr; 43(7):1253-6. PubMed ID: 10753462
[No Abstract] [Full Text] [Related]
35. Poly(2-ethyl-2-oxazoline)-doxorubicin conjugate-based dual endosomal pH-sensitive micelles with enhanced antitumor efficacy.
Li J; Zhou Y; Li C; Wang D; Gao Y; Zhang C; Zhao L; Li Y; Liu Y; Li X
Bioconjug Chem; 2015 Jan; 26(1):110-9. PubMed ID: 25506713
[TBL] [Abstract][Full Text] [Related]
36. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
37. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
38. Novel cleavable cell-penetrating peptide-drug conjugates: synthesis and characterization.
Lelle M; Frick SU; Steinbrink K; Peneva K
J Pept Sci; 2014 May; 20(5):323-33. PubMed ID: 24677287
[TBL] [Abstract][Full Text] [Related]
39. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles.
Min Y; Li J; Liu F; Yeow EK; Xing B
Angew Chem Int Ed Engl; 2014 Jan; 53(4):1012-6. PubMed ID: 24311528
[TBL] [Abstract][Full Text] [Related]
40. Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and Formaldehyde.
Barthel BL; Mooz EL; Wiener LE; Koch GG; Koch TH
J Med Chem; 2016 Mar; 59(5):2205-21. PubMed ID: 26881291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
